US2022315560A1PendingUtilityA1

Inhibitors of ret

77
Assignee: BLUEPRINT MEDICINES CORPPriority: Nov 2, 2015Filed: Feb 11, 2022Published: Oct 6, 2022
Est. expiryNov 2, 2035(~9.3 yrs left)· nominal 20-yr term from priority
Inventors:Jason D. BrubakerJoseph L. KimKevin J. WilsonDouglas WilsonLucian V. Dipietro
A61P 43/00A61P 35/00C07D 405/14C07D 401/14C07D 403/14C07D 239/30A61K 31/506A61K 31/4439C07D 239/36C07D 239/38C07D 239/34C07D 403/12
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Claims

exact text as granted — not AI-modified
1 - 19 . (canceled) 
     
     
         20 . A compound which is:

Join the waitlist — get patent alerts

Track US2022315560A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.